At the 2025 Veeva Commercial Summit in Madrid, life sciences leaders convened to explore how generative and agentic AI are reshaping the commercial model. The event opened with a striking statistic: 92% of major pharmaceutical companies plan to increase product launches significantly in the next five years, yet nearly all intend to keep headcount flat. Against this backdrop, Veeva framed its mission as an industry partner delivering the “industry cloud for life sciences,” built on software, data, and business expertise.
Executives underscored the scale of the challenge — launching more therapies across new therapeutic areas, adopting modern go-to-market models, and sustaining productivity without additional human resources. The summit’s central theme was clear: embedding AI within daily workflows will be key to unlocking enterprise-wide productivity gains of up to 30%.
The Next Wave of Agentic AI
Veeva’s Vice President of Commercial Strategy for Europe, Philipp Luik, described the transformation already underway: from reactive analytics to predictive, intelligent systems that anticipate customer needs, automate decisions, and personalize engagement at scale. Agentic AI, he said, represents a once-in-a-generation opportunity for commercial teams to move beyond efficiency — to rethink how work gets done fundamentally.
The discussion distinguished between early experimentation with generative AI and the emerging paradigm of deeply embedded, autonomous agents. These AI agents can set goals, initiate tasks, and work collaboratively across systems, transforming areas from content review to territory planning.
By integrating these capabilities directly into its commercial cloud, Veeva aims to eliminate the limitations of traditional overlay AI tools. The new approach ensures that agents inherit business logic, compliance controls, and contextual data natively from within the platform — a shift from supplemental intelligence to systemic intelligence.
Embedded Intelligence: Redefining CRM and Engagement
The live demonstration of Veeva Vault CRM showcased what embedded agentic AI looks like in action. Through a new “Activity View,” users can manage priorities with automatically generated, AI-sorted alerts — from meeting requests to dynamically updated target lists.
One example highlighted a representative preparing for an HCP visit. AI-generated insights provided contextual engagement plans, relationship maps showing which colleagues had the strongest connections with the physician, and automatically generated summaries of relevant materials. During the call preparation, the system pre-filled agendas, proposed key talking points, and selected content aligned with previous interactions.
After the meeting, the representative dictated a voice note summarizing the discussion. The AI transcribed, structured, and verified the entry for compliance — flagging a potential issue where patient information was inadvertently mentioned. The autonomous compliance agent immediately alerted the user, demonstrating how generative AI can enhance speed without compromising governance.
These features collectively exemplify how embedded AI transforms CRM from a passive data repository into a proactive partner, guiding users toward the most impactful actions in real time.
The Rise of the Unified Industry Cloud
Veeva’s broader strategy rests on four interconnected clouds — Development, Quality, Commercial, and Data — each built on the same architectural foundation. The Commercial Cloud, the focus of the Madrid summit, integrates marketing, field engagement, patient CRM, and service center operations within a unified suite.
The company emphasized that this architecture enables real-time synchronization between scientific data and commercial activity, closing the loop between R&D innovation and market execution. Over 100 life sciences customers, including nine of the top 20 global pharmaceutical firms, have already adopted Vault CRM, with major deployments at Bayer and GSK.
Customer case studies illustrated the shift toward agility. One European organization completed a full-scale, same-day rollout across all affiliates — a “big bang” implementation that standardized engagement models and enabled AI-powered insights globally. Another highlighted the adoption of Veeva Campaign Manager to unify omnichannel marketing execution across field and digital channels.
Data Cloud and the Precision Frontier
The summit also unveiled updates to Veeva Data Cloud, positioning it as the foundation for precision engagement. Built on modern data models and an open Common Data Architecture (CDA), the platform integrates datasets from multiple domains — including HCP360, a global prescriber database with advanced segmentation capabilities and consented contact attributes.
Early adopters report sales performance gains of 5–15% by shifting focus from over-contacted healthcare professionals to those with high influence but previously low engagement. By connecting HCP360 with CRM, users can now orchestrate dynamic, AI-driven customer journeys that align messaging, timing, and channel with individual preferences.
This integrated data and software ecosystem supports compliance-ready omnichannel orchestration, allowing AI agents to execute micro-decisions across thousands of customer interactions in real time — effectively industrializing personalization at scale.
Continuous Innovation and the AI Roadmap
Veeva reaffirmed its commitment to delivering continuous innovation across its product lines. New standardized AI agents, developed and maintained by Veeva’s product teams, will address recurring industry challenges such as pre-call planning, media content summarization, voice-based data entry, and real-time promotional content compliance through the “Quick Check” agent.
The first wave of these agents will be released in December 2025, followed by iterative quarterly improvements. Each will be fully configurable to align with enterprise-specific workflows, mirroring the evolution of Veeva’s existing application logic.
Beyond CRM, Veeva highlighted its growing Vault Medical Suite, including modules for medical information, communications, and now publications management — extending the AI transformation across the medical affairs domain. The forthcoming Commercial Insights module will enable leadership teams to detect trends from aggregated field signals and align strategic decisions with on-the-ground realities.
Is the Industry Ready for This Level of AI?
Despite the excitement, some questioned whether life sciences is truly ready for embedded agentic AI. Most organizations still wrestle with fragmented data, rigid compliance systems, and uneven digital maturity across affiliates. Without harmonized data and retrained teams, even the smartest agents risk amplifying inconsistencies rather than eliminating them. The technology is there — but readiness, governance, and trust may prove to be the real barriers to realizing that 30% productivity gain.
The Future of Life Sciences Productivity
The 2025 Commercial Summit signaled a decisive turning point for life sciences commercial operations. As pharmaceutical companies prepare for an unprecedented wave of launches without proportional increases in workforce, deeply embedded AI — not just added intelligence — will define the next decade of competitive advantage.
Veeva’s vision of natively integrated agentic AI offers a blueprint for how the sector can sustain innovation at scale: automating the routine, amplifying human expertise, and enabling life sciences organizations to achieve more with the same resources.
As the keynote concluded, the message resonated across Madrid: the industry’s future will not be built on more tools — but on smarter systems that think, act, and adapt alongside the people who use them.
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
